Douglas CDMO Capacity Update January 2025: Small Molecule

Douglas CDMO, proudly based in New Zealand, offers fully integrated, end-to-end drug development and manufacturing services designed to meet the complex needs of today’s pharmaceutical industry. We specialize in high-potency small molecule formulations, including softgels, liquids, and semi-solids, as well as new chemical entities (NCEs) and branded generics. Our expertise spans the entire drug development lifecycle, from formulation and process development to clinical and commercial-scale manufacturing.

With a strong focus on high-value therapeutic areas, Douglas CDMO excels in the production of prescription drugs targeting oncology, dermatology, the central nervous system, and immunity. Our advanced facilities and cutting-edge technologies enable us to handle complex and sensitive formulations while maintaining the highest standards of quality, safety, and compliance.

What sets Douglas CDMO apart is our commitment to innovation and partnership. By leveraging our extensive experience, flexible capabilities, and client-focused approach, we help our partners accelerate time-to-market and achieve successful outcomes for their therapies. Whether you are advancing a new chemical entity or optimizing an established product, Douglas CDMO is your trusted partner in transforming ideas into impactful medicines.